Overview

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Status:
Completed
Trial end date:
2017-08-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide
Immunoglobulin Fc Fragments
Metformin